||1R21CA258218-01A1 Interpret this number
||University Of California, San Francisco
||Predicting the Likelihood of Immune-Related Adverse Events in Breast Cancer Patients
Immuno-oncology agents have clearly improved rates of response in triple negative breast cancer (TNBC)
patients. However, these improvements come at a cost -- 10-25% of patients will experience an immune-related
adverse event (irAEs). These AEs do not appear to be associated with response and appear idiosyncratic.
Adrenal insufficiency, for example, can appear late when patients are extremely symptomatic and have a cortisol
near zero that can lead fatality if improperly treated. The ability to identify individual patients or subsets of patients
who are at increased or high risk of these toxicities will improve outcomes and reduce harm in several ways.
Those at highest risk may avoid treatment with certain immunotherapies, while those at increased risk could be
flagged for closer monitoring or placed upon prophylactic interventions to avoid or downgrade the AE. The use
of demographic, biologic and genetic information in this way is in keeping with precision oncology efforts.
The cancer-focused question we are addressing is whether we can predict the likelihood of individuals
experiencing serious immune-related adverse events following cancer immunotherapy using age, comorbidities,
electronic health record (EHR) data, quality of life (QOL), adverse events (AE), and genetic variations. We
hypothesize that early insight into which patients will experience irAEs can be generated by predictive analytics
embedded within a decision-support framework. The overall goals of this proposal are to: (1) decipher early
which patients are going to experience thyroid disease, pneumonitis, pruritus, colitis, hepatoxicity, or adrenal
failure and ultimately affect quality of life; and (2) better understand the genetic profile that underlies patients'
risk of developing irAEs.
We will use a rich multidimensional data from the I-SPY2 trial in early breast cancer. Due to its adaptive
platform design, I-SPY2 provides the opportunity to study multiple immunotherapies within in the same study,
using standard methodologies across multiple sites. We propose to: 1) develop and evaluate a holistic
approach and resulting decision support algorithm, designed for clinician-researchers who help manage the
care of patients undergoing immunotherapy, 2) determine both novel and annotated single nucleotide
polymorphisms (SNPs) associated with irAEs, and 3) validate the decision support algorithm in two new
experimental arms. Our computational models will be trained on information from 500 I-SPY2 breast cancer
trial patients undergoing immunotherapy. Successful completion of this work will increase our understanding of
the clinical, patient-reported, and genetic factors underlying irAEs and enable early prediction of who is at risk
before therapy is initiated.